Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | HTR2B | P41595 | 4/20 | 0.44 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14200094 | 0.85 | HTR2A (0.39) | HTR2AHTR2CHTR2BTUBB1NFE2L2 | |
| SCHEMBL23771986 | 0.84 | HTR2A (0.38) | HTR2AHTR2CHTR2BTUBB1NFE2L2 | |
| SCHEMBL10300148 | 0.83 | HTR2A (0.41) | HTR2AHTR2CHTR2BTUBB1LMNA | |
| SCHEMBL15780820 | 0.82 | HTR2A (0.45) | HTR2AHTR2CHTR2BMAPK1HTT | |
| SCHEMBL12678823 | 0.82 | NQO2 (0.36) | HTR2AHTR2CHTR2BTUBB1NFE2L2 | |
| SCHEMBL802723 | 0.81 | HTR2A (0.44) | HTR2AHTR2CHTR2BTUBB1NFE2L2 | |
| SCHEMBL2955217 | 0.81 | CA2 (0.43) | TUBB1LMNAMAPK1HTTRAB9A | |
| SCHEMBL29114193 | 0.80 | HTR2A (0.40) | HTR2AHTR2CHTR2BTUBB1LMNA | |
| SCHEMBL27403256 | 0.79 | HTT (0.46) | HTR2AHTR2CHTR2BLMNAMAPK1 | |
| SCHEMBL12871808 | 0.79 | CES2 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20210188869-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2021-06-24 | — | — | US | disclosed |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200102321-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2020-04-02 | — | — | US | disclosed |
| US-20190262342-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2019-08-29 | — | — | US | disclosed |
| US-10370386-B2 | Substituted quinolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2019-08-06 | — | — | US | disclosed |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-8835423-B2 | Azepine inhibitors of janus kinases | INCYTE CORPORATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140031344-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION (US) | 2014-01-30 | — | — | US | disclosed |
| US-8563541-B2 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120329782-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION (US) | 2012-12-27 | — | — | US | disclosed |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | HTR2A 4524/4885HTR2C 4641/4885HTR2B 4522/4885 |
| US-20120329782-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | HTR2A 3849/4885HTR2C 3835/4885HTR2B 4259/4885 |
| US-20210188869-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | HTR2A 4367/4885HTR2C 4608/4885HTR2B 3707/4885 |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | HTR2A 4250/4885HTR2C 3449/4885HTR2B 2870/4885 |
| US-20200102321-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | HTR2A 3636/4885HTR2C 3541/4885HTR2B 3343/4885 |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | HTR2A 3636/4885HTR2C 3541/4885HTR2B 3343/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | HTR2A 4367/4885HTR2C 4608/4885HTR2B 3707/4885 |
| US-10370386-B2 | Substituted quinolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | HTR2A 3364/4885HTR2C 3150/4885HTR2B 2493/4885 |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | HTR2A 4367/4885HTR2C 4608/4885HTR2B 3707/4885 |
| US-20190262342-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | HTR2A 4760/4885HTR2C 4683/4885HTR2B 4778/4885 |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | KRAS, NRAS, HRAS | HTR2A 4524/4885HTR2C 4641/4885HTR2B 4522/4885 |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | HTR2A 3849/4885HTR2C 3835/4885HTR2B 4259/4885 |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | HTR2A 4760/4885HTR2C 4683/4885HTR2B 4778/4885 |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | JAK1, JAK3, JAK2 | HTR2A 3849/4885HTR2C 3835/4885HTR2B 4259/4885 |
| US-20140031344-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | HTR2A 3849/4885HTR2C 3835/4885HTR2B 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.